Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Suppression of Idol expression is an additional mechanism underlying statin-induced up-regulation of hepatic LDL receptor expression

10 Nov 2010

Abstract excerpt

Recent studies have identified proprotein convertase subtilisin/kexin type 9 (PCSK9) and Idol as negative regulators of low density lipoprotein receptor (LDLR) protein stability. While the induction of PCSK9 transcription has been recognized as a limitation to the statin cholesterol-lowering efficacy at higher doses, it is unknown whether Idol is involved in the statin-mediated up-regulation of the hepatic LDLR....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis C virus research
Share to Lipoproteins and Cardiovascular Health
Share to Protein Kinase Regulation and GTPase Signaling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21069265
DOI: 10.3892/ijmm.2010.559

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Suppression of Idol expression is an additional mechanism underlying statin-induced up-regulation of hepatic LDL receptor expressionPMID 21069265Read ↗

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.Semantic proximity Read ↗

Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells.Semantic proximity Read ↗

Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.Semantic proximity Read ↗

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.Semantic proximity Read ↗

Targeted disruption of the idol gene alters cellular regulation of the low-density lipoprotein receptor by sterols and liver x receptor agonists.Semantic proximity Read ↗

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.Semantic proximity Read ↗

Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.Semantic proximity Read ↗

Inclisiran—Silencing the Cholesterol, Speaking up the PrognosisSemantic proximity Read ↗

PCSK9 dysregulates cholesterol homeostasis and triglyceride metabolism in olanzapine-induced hepatic steatosis via both receptor -dependent and -independent pathwaysSemantic proximity Read ↗

Statins Upregulate PCSK9 , the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial HypercholesterolemiaSemantic proximity Read ↗

Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation.Semantic proximity Read ↗

Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.